中重度特应性皮炎青少年和成人瘙痒、皮肤疼痛及睡眠障碍患者报告结局量表的内容评估:定性访谈
本研究通过两阶段定性访谈评估5种特应性皮炎(AD)相关患者报告结局量表(PROMs)在中重度AD青少年和成人中的内容效度。27名成人和20名青少年参与,结果显示修订版最严重瘙痒NRS(1.1)、修订版AD皮肤疼痛NRS(1.1)、睡眠障碍NRS、皮肤疼痛特异性PGIC和PGIS在≥12岁中重度AD患者中具有内容效度,且瘙痒、皮肤疼痛和睡眠障碍是relevant且重要的评估领域。
要点
- 修订版最严重瘙痒NRS(1.1)等5种PROMs在≥12岁中重度AD患者中内容效度获支持。
- 瘙痒、皮肤疼痛和睡眠障碍是中重度AD青少年和成人relevant且重要的评估领域。
- 成人和青少年对AD症状的体验总体一致。
核心结论
- 研究结果支持修订版最严重瘙痒NRS(1.1)、修订版AD皮肤疼痛NRS(1.1)、睡眠障碍NRS、皮肤疼痛特异性PGIC和皮肤疼痛特异性PGIS在≥12岁中重度AD患者中的内容效度。
- 瘙痒、皮肤疼痛和睡眠障碍对中重度AD青少年和成人relevant且重要。
研究设计与样本
- 定性研究,在中重度AD青少年(12-17岁)和成人(≥18岁)中分两阶段连续进行,每阶段两轮个体访谈,含概念引出和认知 debriefing。
- 初始内容评估(阶段1)纳入27名成人和20名青少年,评估最严重瘙痒NRS(1.0)和AD皮肤疼痛NRS(1.0)(n=26;16名成人,10名青少年)。
- 后续内容评估(阶段2)纳入21名参与者(11名成人,10名青少年),评估修订版最严重瘙痒NRS(1.1)、修订版AD皮肤疼痛NRS(1.1)、睡眠障碍NRS、皮肤疼痛特异性PGIC和皮肤疼痛特异性PGIS。
主要发现
- 成人和青少年参与者的结果总体一致。
- 睡眠障碍在中重度AD成人和青少年中relevant且重要(阶段2),瘙痒和皮肤疼痛的重要性在阶段1和2得到进一步确认。
临床怎么用
- 在临床 trials 中可使用修订版最严重瘙痒NRS(1.1)、修订版AD皮肤疼痛NRS(1.1)、睡眠障碍NRS、皮肤疼痛特异性PGIC和PGIS评估≥12岁中重度AD患者的瘙痒、皮肤疼痛和睡眠障碍。
- 关注中重度AD青少年和成人的瘙痒、皮肤疼痛和睡眠障碍,因其造成重大问题和困扰。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pruritus, skin pain and sleep disturbance place a significant burden on individuals with moderate-to-severe atopic dermatitis (AD) and negatively affect their quality of life. Fit-for-purpose patient-reported outcome measures (PROMs) that assess AD-related pruritus, skin pain and sleep disturbance are important for evaluating the effectiveness of new AD treatments. OBJECTIVES: To evaluate the content validity of five AD-related PROMs in adolescents and adults with moderate-to-severe AD [the Worst Pruritus Numeric Rating Scale (NRS), the AD Skin Pain NRS, the Sleep Disturbance NRS, the skin pain-specific Patient Global Impression of Change (PGIC) and the skin pain-specific Patient Global Impression of Severity (PGIS)], and to assess patient-reported experience with pruritus, skin pain and sleep disturbance. METHODS: A qualitative study in adolescents (aged 12-17 years) and adults (aged ≥ 18 years) with moderate-to-severe AD was conducted in two consecutive stages. In each stage, two iterative rounds of individual interviews were conducted by experienced interviewers. All interviews included concept elicitation and cognitive debriefing components. Data were analysed using thematic analysis. RESULTS: Twenty-seven adults and 20 adolescents with moderate-to-severe AD took part in the initial content evaluation (stage 1) of the Worst Pruritus NRS (1.0) and AD Skin Pain NRS (1.0) (n = 26; 16 adults, 10 adolescents) and in the subsequent content evaluation (stage 2) of the revised Worst Pruritus NRS (1.1), revised AD Skin Pain NRS (1.1), Sleep Disturbance NRS, skin pain-specific PGIC and skin pain-specific PGIS (n = 21; 11 adults, 10 adolescents). The results were generally aligned and consistent for adult and adolescent participants. Additionally, we found that sleep disturbance is relevant and important for evaluation in adults and adolescents with moderate-to-severe AD (stage 2), while also providing further confirmation of this for pruritus and skin pain (stages 1 and 2). CONCLUSIONS: Our findings support the content validity of the revised Worst Pruritus NRS (1.1), revised AD Skin Pain NRS (1.1), Sleep Disturbance NRS, skin pain-specific PGIC and skin pain-specific PGIS in individuals aged ≥ 12 years with moderate-to-severe AD. Furthermore, the findings support sleep disturbance, skin pain and pruritus as being relevant and important for adolescents and adults with moderate-to-severe AD. Atopic dermatitis (or ‘AD’ for short) is also known as ‘eczema’. It causes itchy, dry and painful or inflamed skin. AD affects millions of people in the USA and many cases are moderate or severe. As treatments for AD are developed, clinical trials need ways to measure how well a treatment works. Patient-reported outcome measures (or ‘PROMs’) are questionnaires answered only by patients that record people's experiences with their condition or treatment. We interviewed 27 adults and 20 adolescents with moderate-to-severe AD to see how well five different PROMs measuring AD symptoms line up with real experiences. Based on their answers, we found that adults and adolescents have similar experiences with AD symptoms, including itch, skin, pain and sleep disturbance. Our results suggest that these PROMs are easy to understand when people with AD are asked about their most important symptoms. The interviews confirmed that itch, skin pain and sleep disturbances cause major problems and disruptions for people with AD. This highlights the need to track these symptoms and their effects in clinical trials for AD treatments.
引用
- Blauvelt A, Reckleff J, Zhao Y, et al. Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews. Br J Dermatol. 2025. PMID: 39365666. doi:10.1093/bjd/ljae346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。